



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

7/15/4  
RECEIVED  
TECH CENTER 1600/2900  
APR 01 2002

Applicants: Paul A. RENHOWE, *et al.*

Date: March 13, 2002

Serial No.: 09/943,382

Docket No.: 072121:0139

Filed: August 30, 2001

Group Art Unit: 1614

For: **HETEROCYCLIC COMPOUNDS**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on March 13, 2002.

\_\_\_\_\_  
Bernard P. Friedrichsen

(Name of applicant, assignee  
or Registered Representative)

\_\_\_\_\_  
*Bernard P. Friedrichsen*

(Signature)

\_\_\_\_\_  
March 13, 2002

(Date of Signature)

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Submitted herewith on Form PTO-1449 and presented below is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 C.F.R. §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 C.F.R. §§1.97 and 1.98.



## UNITED STATES PATENTS

<u>Inventor(s)</u>	<u>Patent No.</u>	<u>Date Issued</u>
Von Der Saal, et al.	5,414,088	May 9, 1995

## FOREIGN PATENTS

<u>Patent No.</u>	<u>Publication Date</u>	<u>Country</u>
EP 0 290 153	Nov. 9, 1988	EP
WO 97/03069	Jan. 30, 1997	PCT

## OTHER DOCUMENTS

Maguire, M. P., et al., "A New Series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Substituted Quinoline Derivatives," *J. Med. Chem.*, Vol. 37, No. 14, pp. 2129-2137, 1994; published by American Chemical Society, Washington, D.C.

Hennequin, L. F., et al., "Design and Structure - Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors," *J. Med. Chem.*, Vol. 42, No. 26, pp. 5369-5389, 1999; published by American Chemical Society, Washington, D.C.

Stover, D. R., "Recent advances in protein kinase inhibition: Current molecular scaffolds used for inhibitor synthesis," *Current Opinion in Drug Discovery & Development*, Vol. 2, No. 4, pp. 274-285, 1999; published by PharmaPress Ltd., London, United Kingdom.

## REMARKS

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that this document is considered material to patentability as defined in 37 C.F.R. §1.56. Patentee does not waive any right to take any action which would be

RECEIVED  
APR 01 2002  
TECH CENTER 1600/2900

appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

No Office Action on the merits has yet been received by Applicants. Therefore, Applicants believe that this Supplemental Information Disclosure Statement is submitted in compliance with 37 C.F.R. § 1.97 (b)(3). In the event that an Office Action on the merits has been mailed to Applicants, Applicants note that each item of information contained in the Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the Information Disclosure Statement in accordance with 37 C.F.R. § 1.97(c)(1). Applicants believe that no fee is due for this filing. However, the Commissioner is authorized to charge any fee due for this filing to Deposit Account No. 06-1447. For purposes of charging said Deposit Account, a duplicate copy of this Statement is enclosed.

Each of these documents was cited in the International Search Report mailed March 06, 2002, by the European Patent Office on a Patent Cooperation Treaty application that relates to the above-referenced application. A copy of the Search Report is also enclosed. The other documents cited in the International Search Report were previously submitted to the Patent and Trademark Office in an Information Disclosure Statement filed on February 26, 2002. It is thus requested that these documents be considered during examination of the above-referenced application and be specifically made of record therein.

Respectfully Submitted,

March 13, 2002

Date

**Direct correspondence to:**

David P. Lentini, Reg. No. 33,944


Attorney for Applicant

CHIRON CORPORATION

Intellectual Property - R440

P.O. Box 8097

Emeryville, California 94662-8097



Bernard P. Friedrichsen, Reg. No. 44,689

Foley & Lardner

150 East Gilman Street

P.O. Box 1497

Madison, Wisconsin 53701-1497

Tel: (608) 258-4281

Fax: (608) 258-4258